E
Anebulo Pharmaceuticals, Inc. ANEB
$1.14 $0.065.56% NASDAQ
Recommendation
Prev Close
$1.14
Volume
8,525
Avg Vol (90D)
36,076
Market Cap
$46.84M
Dividend & Yield
--
52-Week Range
$0.8001 - $3.20
P/E (TTM)
--
EPS (TTM)
-$0.2906
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Mangrove Partners IM, LLC Acquires Significant Stake in Anebulo Pharmaceuticals Inc
3/21/2025 - GuruFocus
King Luther Capital Management Corp Makes New Investment in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB)
3/15/2025 - Ticker Report
Anebulo Pharmaceuticals files to sell 15.15M shares of common stock for holders
2/20/2025 - The Fly
Nantahala Capital Management, LLC's Strategic Acquisition in Anebulo Pharmaceuticals Inc.
2/15/2025 - GuruFocus
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates
2/14/2025 - GuruFocus
Anebulo Pharmaceuticals reports Q4 EPS (9c) vs. (11c) last year
2/14/2025 - The Fly
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates
2/14/2025 - Business Wire
Anebulo Pharmaceuticals Leads This Trio Of US Penny Stocks
2/4/2025 - Simply Wall St
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Update
1/14/2025 - Ticker Report
Buffett Is Still Buying, Plus Insiders Love These 2 Biotech Stocks
12/29/2024 - 24/7 Wall St.
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Director Purchases $9,999,999.90 in Stock
12/27/2024 - Ticker Report
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Director Purchases $9,999,999.90 in Stock
12/27/2024 - MarketBeat
Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute ...
12/23/2024 - GuruFocus
Anebulo Pharmaceuticals collaborates with FDA to advance selonabant
12/23/2024 - TipRanks Financial Blog
Anebulo Pharmaceuticals collaborates with FDA to advance selonabant
12/23/2024 - The Fly
Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise
12/23/2024 - Business Wire
Anebulo Pharmaceuticals (NASDAQ:ANEB) Receives Speculative Buy Rating from Benchmark
11/23/2024 - Ticker Report
Anebulo Pharmaceuticals Advances Cannabis Toxicity Solutions
11/16/2024 - TipRanks Financial Blog
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates
11/13/2024 - Business Wire
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Update
10/30/2024 - Ticker Report
Anebulo Pharmaceuticals (NASDAQ:ANEB) Stock Rating Reaffirmed by Benchmark
10/1/2024 - Ticker Report
Anebulo Pharmaceuticals (NASDAQ:ANEB) Stock Rating Reaffirmed by Benchmark
10/1/2024 - MarketBeat - AP News
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Up 27.7% in September
9/28/2024 - Zolmax
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Sees Significant Increase in Short Interest
9/28/2024 - Ticker Report
Anebulo Pharmaceuticals (NASDAQ:ANEB) Announces Earnings Results
9/26/2024 - Zolmax
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
-$8.01M
Net Income (TTM)
-$7.67M
Balance Sheet
Total Assets (Q)
$15.84M
Total Debt (Q)
$0.00
Total Liabilities (Q)
$878.80K
Book Value Per Share (Q)
$0.3642
Cash Flow
Cash from Operations (TTM)
-$6.65M
Cash from Investing (TTM)
--
Cash from Financing (TTM)
$15.00M
Net Change in Cash (TTM)
$8.35M
Filings
Filing Date
Friday, February 14, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 12 and 16 (est)
Price History
Loading...
Beta
0.86
7-Day Total Return
9.62%
30-Day Total Return
-33.33%
60-Day Total Return
-28.30%
90-Day Total Return
-18.57%
Year to Date Total Return
-27.85%
1-Year Total Return
-57.83%
2-Year Total Return
-59.29%
3-Year Total Return
-72.40%
5-Year Total Return
--
52-week Low
Dec 20, 2024 - $0.8001
52-week High
May 02, 2024 - $3.20
Valuation
Market Cap
$46.84M - Nano Cap
Enterprise Value
$31.84M
Price/Sales (TTM)
--
Price/Book (Q)
3.13
Dividends and Shares
Shares Outstanding
27.42M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.anebulo.com
Phone Number
512 598 0931
Address
1017 Ranch Road 620 South
Lakeway, TX 78734
Country
United States
Year Founded
2020
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute... more
NASDAQ 04/25/2025 4:00PM Eastern Quotes delayed